In a groundbreaking, head-to-head trial, Eli Lilly's Mounjaro was proven to be as effective as Trulicity in protecting patients with type 2 diabetes and heart disease from major cardiovascular events like heart attack, stroke, and cardiovascular death. The SURPASS-CVOT trial, which is the largest and longest study of Mounjaro to date, involved over 13,000 participants and compared the GIP/GLP-1 dual agonist Mounjaro to the GLP-1 receptor agonist Trulicity. The results showed that Mounjaro met the primary objective by demonstrating a non-inferior rate of these cardiovascular events, meaning it was at least as good as Trulicity in terms of cardiovascular safety.

Beyond its cardiovascular benefits, Mounjaro also showed significant improvements on several key health measures compared to Trulicity. The trial found that Mounjaro provided greater benefits in controlling A1C and weight, improving kidney function, and reducing the overall risk of death. Specifically, the risk of all-cause mortality was 16% lower for Mounjaro patients, and the risk of a major cardiovascular event was 8% lower. These findings, according to a Lilly executive, strengthen Mounjaro's position as a potential first-line treatment for individuals with type 2 diabetes and cardiovascular disease.